Molina Healthcare (MOH) Q2 2026 earnings review
Medicare Saves the Quarter as Marketplace Bleeds
Molina's Q2 2026 results confirm management's narrative that this year is the 'trough' for margins. Adjusted EPS of $1.51 beat internally lowered bars, prompting a slight $0.25 bump to FY26 guidance (now $5.25). This stabilization was heavily reliant on Medicare outperformance, which completely offset a devastating $1.50 EPS drag from a deteriorating Marketplace segment. Premium revenue is decelerating (-6% YoY) due to deliberate membership attrition, but operating cash flows have strongly reversed to positive. While the core Medicaid rate-trend imbalance appears to have finally stabilized, the total collapse of Marketplace profitability remains a glaring risk.
🐂 Bull Case
The core Medicaid MCR landed exactly on expectations at 92.7%. The severe imbalance between state rates and medical cost trend has stabilized, setting the foundation for the promised 2027 margin recovery.
Medicare MCR of 90.7% significantly beat expectations. The decision to abandon the traditional MAPD product to focus strictly on the dual-eligible population added $1.50 to the full-year segment EPS outlook.
🐻 Bear Case
Marketplace MCR spiked to 88.9%, forcing management to slash the segment's full-year EPS guidance by $1.50. The risk pool's acuity remains highly toxic despite aggressive footprint reductions.
Premium revenue contracted 6% YoY as total membership dropped from 5.7 million to 4.9 million. If state rate restorations fall short, this smaller base will generate heavy negative operating leverage.
⚖️ Verdict: ⚪
Neutral. Molina is successfully navigating the Medicaid redetermination hangover, and the Medicare pivot is proving highly resilient. However, the Marketplace segment remains deeply problematic, and top-line contraction limits near-term upside until 2027 rate resets take full effect.
Key Themes
Medicaid Imbalance Bottoming Out
The core business is stabilizing. Medicaid MCR came in at 92.7%, strictly in line with expectations. Management noted the macro imbalance between state funding rates and medical cost trend 'appears to have stabilized.' This is the critical linchpin for Molina: the company's entire bull case relies on 2026 serving as the margin floor before 2027 rate adjustments force state reimbursements to catch up to utilization.
Medicare Portfolio Optimization Paying Off
Medicare was the standout performer, with MCR dropping to 90.7%—beating expectations on lower medical cost trends and better 2026 pricing. This segment effectively saved the quarter, generating a $1.50 upward revision to its full-year EPS contribution. The planned 2027 exit from the traditional MAPD product to focus exclusively on the high-acuity dual-eligible population is proving to be an effective strategy.
Operating Cost Discipline Under Pressure
Despite top-line deceleration, management held the adjusted G&A ratio to 6.5%. While this is slightly higher than the 6.1% posted a year ago due to fixed-cost deleveraging, it demonstrates strict cost containment, which is providing a necessary buffer against elevated medical care ratios.
Marketplace Acuity Collapse
The ACA segment is actively bleeding and directly contradicts the 'trough is in' narrative for the overall business. MCR spiked to 88.9%, driven by unfavorable prior-year risk adjustments and a terrible current-year member acuity mix. This sliced $1.50 per share off the segment's outlook, completely erasing the gains from Medicare. Despite shrinking membership drastically, the remaining risk pool is toxic.
Membership Base Decelerating
Total membership dropped significantly to 4.92 million, down from 5.74 million a year ago. While some of this stems from the intentional paring back of the unprofitable Marketplace segment (down to 283k), the core Medicaid segment also shed ~350,000 members YoY. This volume loss requires strict monitoring, as it threatens to impair future earnings leverage when margins eventually recover.
Near-Term Earnings Drags Persist
The full-year guidance remains heavily burdened by two specific structural weights: a $1.50 per share loss related to the Q4 implementation of the massive new Florida CMS Medicaid contract, and a $1.00 per share drag from the underperforming MAPD product that won't roll off until the 2027 exit.
Other KPIs
Reversing. Operating cash flow violently swung to a positive $788 million for the first six months of 2026, compared to a $112 million outflow in the prior year period. Management attributed the surge to favorable timing of government receivables and payables. Days in claims payable remained steady at 44 days, quelling concerns over aggressive claims denial tactics to preserve cash.
Accelerating. Parent company cash grew from $223 million at the end of 2025 to $290 million, indicating that subsidiary health plans are successfully generating enough excess capital to dividend back up to the holding company. This supports the narrative that the core business remains fundamentally cash-generative despite GAAP margin compression.
Guidance
Accelerating from prior guidance of 'at least $5.00', though it still represents a massive ~52% YoY decline from FY25's $11.03. The $0.25 net increase reflects Medicaid's H1 beat. The massive segment shifts under the hood (+ $1.50 Medicare, - $1.50 Marketplace) highlight ongoing portfolio volatility.
Stable. The premium revenue target is entirely unchanged, implying a roughly 2% YoY contraction from FY25's $43.05 billion. This confirms that the severe membership pruning strategy in the Marketplace is already fully baked into the baseline.
Key Questions
Marketplace Viability
Given the persistent $1.50 EPS drag and highly toxic acuity mix despite aggressive footprint reductions, what is the strategic rationale for remaining in the ACA Marketplace rather than fully exiting, as you did with MAPD?
Florida Contract Implementation Risk
The $1.50 EPS drag for the Florida Medicaid contract is primarily embedded in H2. Are startup costs tracking strictly to plan, or is there risk of further margin dilution upon the actual Q4 launch?
2027 Rate Update Visibility
With the Medicaid trend finally stabilizing at an elevated level, what early indications are states providing regarding off-cycle or 2027 rate increases to definitively close the current structural funding gap?